Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TORIPALIMAB for Bladder cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 33 adverse event reports in the FDA FAERS database where TORIPALIMAB was used for Bladder cancer.

Most Reported Side Effects for TORIPALIMAB

Side Effect Reports % Deaths Hosp.
Myelosuppression 590 43.9% 3 432
Off label use 276 20.5% 29 137
White blood cell count decreased 144 10.7% 0 74
Anaemia 67 5.0% 17 8
Hypothyroidism 67 5.0% 13 11
Neutrophil count decreased 67 5.0% 0 25
Nausea 60 4.5% 7 14
Rash 59 4.4% 7 11
Vomiting 58 4.3% 7 14
Platelet count decreased 53 3.9% 3 30
Diarrhoea 50 3.7% 6 16
Neutropenia 49 3.7% 8 1
Thrombocytopenia 48 3.6% 12 0
Pyrexia 46 3.4% 2 13
Decreased appetite 43 3.2% 9 9

Other Indications for TORIPALIMAB

Nasopharyngeal cancer (163) Hepatocellular carcinoma (125) Oesophageal carcinoma (72) Lung neoplasm malignant (65) Breast cancer (40) Malignant melanoma (36) Small cell lung cancer (36) Hepatic cancer (34) Renal cancer (34) Oesophageal squamous cell carcinoma stage iv (29)

Other Drugs Used for Bladder cancer

BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (1,279) PEMBROLIZUMAB (869) GEMCITABINE (841) CISPLATIN (780) ENFORTUMAB VEDOTIN-EJFV (530) NIVOLUMAB (512) ATEZOLIZUMAB (487) CARBOPLATIN (332) BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (326) GEMCITABINE\GEMCITABINE (240)

Related Pages

TORIPALIMAB Full Profile All Bladder cancer Drugs TORIPALIMAB Demographics TORIPALIMAB Timeline